Patent intelligence · US
US 11713324
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Patent details — US 11713324
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 1, 2023
- Expiration
- Jul 27, 2043
- Applicant
- Neurocrine Biosciences, Inc.
- Claims
- 2
- CPC classes
- A61P, A61P1/00, A61P1/04, A61P11/00
Quick answer
US 11713324 (Gonadotropin-releasing hormone receptor antagonists and methods relating thereto) is held by Neurocrine Biosciences, Inc.. Status: granted. Granted Aug 1, 2023. Expires Jul 27, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Neurocrine Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61P, A61P1/00, A61P1/04, A61P11/00, A61P13/02, A61P13/08
More from Neurocrine Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421193
GPR52 modulators and methods of use
granted -
US 12383536
CRF receptor antagonists and methods of use
granted -
US 12128033
Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
granted -
US 12102637
Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 12083227
Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 11730739
Treatment of congenital adrenal hyperplasia
granted -
US 11718618
Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors
granted
Frequently asked questions
What is US patent 11713324?
US 11713324 (Gonadotropin-releasing hormone receptor antagonists and methods relating thereto) is held by Neurocrine Biosciences, Inc.. Status: granted. Granted Aug 1, 2023. Expires Jul 27, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11713324?
Neurocrine Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 111 pharmaceutical patents for this assignee.
When does US 11713324 expire?
Our index shows an expiration date of Jul 27, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.